Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016:2016:3058393.
doi: 10.1155/2016/3058393. Epub 2016 Sep 8.

Inositols in the Treatment of Insulin-Mediated Diseases

Giovanna Muscogiuri  1 , Stefano Palomba  2 , Antonio Simone Laganà  3 , Francesco Orio  4
Affiliations
Review

Inositols in the Treatment of Insulin-Mediated Diseases

Giovanna Muscogiuri et al. Int J Endocrinol. 2016.

Erratum in

Abstract

A growing body of research is currently focused on the role of inositol isomers and in particular myo-inositol (MYO-INS) and D-chiroinositol (DCI) in the treatment of insulin resistance states. Both isomers have been shown to exert insulin-mimetic action and to lower postprandial glucose. Further, insulin resistance-related diseases were associated to derangements in inositol metabolism. Thus, the aim of this review is to provide current evidence on the potential benefits of inositol isomers (MYO-INS and DCI) in the treatment of disease associated to insulin resistance such as polycystic ovary syndrome (PCOS), gestational diabetes, and metabolic syndrome. Finally, molecular insights into inositol insulin-sensitizing effects will be covered focusing on the possible role of inositol glycans as insulin second messengers.

PubMed Disclaimer

References

    1. Nestler J. E., Jakubowicz D. J., Reamer P., Gunn R. D., Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. The New England Journal of Medicine. 1999;340(17):1314–1320. doi: 10.1056/nejm199904293401703. - DOI - PubMed
    1. Unfer V., Carlomagno G., Dante G., Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecological Endocrinology. 2012;28(7):509–515. doi: 10.3109/09513590.2011.650660. - DOI - PubMed
    1. Heimark D., McAllister J., Larner J. Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocrine Journal. 2014;61(2):111–117. doi: 10.1507/endocrj.EJ13-0423. - DOI - PubMed
    1. Di Paolo G., De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature. 2006;443(7112):651–657. doi: 10.1038/nature05185. - DOI - PubMed
    1. Genazzani A. D., Santagni S., Ricchieri F., et al. Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology Research. 2014;40(5):1353–1360. doi: 10.1111/jog.12319. - DOI - PubMed